๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers Clinical trials Ahmedabad
Clinical trial register · India

Clinical Trials in Ahmedabad

Every study on the ClinicalTrials.gov registry that lists a site in India and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 1123 matching records held by the registry are in this view. Synced 21 Sep 2026, 03:16 UTC
1123
Studies in scope
all four open statuses
610
Recruiting now
open to new participants
222
Lead sponsors
across recruiting studies
Top sites
New Delhi 332 Mumbai 259 Hyderabad 237 Bangalore 193 Pune 189
Narrow the registerReset
Recruitment status
Phase
Site location
New Delhi332 Mumbai259 Hyderabad237 Bangalore193 Pune189
All 274 locations
Target enrolment
to
157 of 1123 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Indian sites
Start
Active, closed
A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus
NCT05648500Lupus Erythematosus, Systemic
Viatris Innovation GmbH
Phase 3
470
Ahmedabad, Bangalore, Chennai, Hyderabad, Jaipur, Nagpur, Nashik, Pune
2022-12-13
Active, closed
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (โ‰ฅ18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
NCT05456191Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
Novartis Pharmaceuticals
Phase 3
568
Ahmedabad, New Delhi, Chennai, Varanasi, Rishikesh
2022-11-21
Active, closed
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
NCT05556512Obesity, Overweight
Eli Lilly and Company
Phase 3
15,374
Ahmedabad, Bikaner, Hyderabad, Lucknow, Ludhiana, Mumbai, Nagpur, New Delhi
2022-10-11
Active, closed
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT05514054Breast Neoplasms
Eli Lilly and Company
Phase 3
8,000
Ahmedabad, Bangalore, Belagavi, Bhubaneswar, Chandigarh, Chennai, Hyderabad, Kanpur
2022-10-04
Recruiting
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT05519085Relapsed or Refractory Multiple Myeloma
Celgene
Phase 3
810
Ahmedabad, Gurugram, Belagavi, Mumbai, Madurai, Varanasi, Ludhiana, Puducherry
2022-09-20
Recruiting
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
NCT05511363Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
410
Ahmedabad, New Delhi, Hyderabad
2022-08-23
Active, closed
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
NCT05492578Dermatitis Atopic
Sanofi
Phase 2/3
1,856
Ahmedabad, Belagavi, Chandigarh, Kolkata, Nagpur, Pune
2022-08-22
Recruiting
Pharmacodynamic Equivalence of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate in Adult Patients With Stable Mild Asthma
NCT04912596Mild Asthma
Intech Biopharm Ltd.
Not applicable
148
Ahmedabad, Belagฤve, Kolkata, New Delhi, Pune, Ulhasnagar
2022-08-15
Recruiting
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
NCT05268289Lupus Nephritis
Novartis Pharmaceuticals
Phase 2
240
Ahmedabad, Kozhikode, New Delhi, Vellore, Hyderabad, Lucknow, Puducherry
2022-08-10
Active, closed
Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
NCT05349214Sjogren Syndrome
Novartis Pharmaceuticals
Phase 3
506
Ahmedabad, Bangalore, Pune, New Delhi
2022-08-04
Active, closed
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
NCT05242471Crohn's Disease
Janssen Research & Development, LLC
Phase 2
703
Ahmedabad, Bengaluru, Bhubaneswar, Chennai, Gurgaon, Hyderabad, Mumbai, New Delhi
2022-07-22
Active, closed
A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium
NCT05456425Pterygium
Cloudbreak Therapeutics, LLC
Phase 3
660
Chandigarh, Ahmedabad, Bangalore, Bhubaneswar, Bikaner, Noida
2022-06-30
By invitation
Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
NCT05248659Immunoglobulin A Nephropathy
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2/3
600
Hyderabad, Ahmedabad, Nadiฤd, Bengaluru, Manipal, Kozhikode, Thiruvananthapuram, Pune
2022-04-05
Active, closed
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
NCT05301842Hepatocellular Carcinoma
AstraZeneca
Phase 3
760
Ahmedabad, Bangalore, Delhi, Hyderabad, Jaipur, Kolkata, Mumbai, New Delhi
2022-03-28
Active, closed
COMBINE-INTERVENE: COMBINEd Ischemia and Vulnerable Plaque Percutaneous INTERVENtion to Reduce Cardiovascular Events
NCT05333068Multivessel Coronary Artery Disease, Ischemia, Vulnerable Plaque, Coronary Artery Disease
Diagram B.V.
Not applicable
1,223
Ahmedabad, Bangalore, Chandigarh
2022-03-16
Active, closed
Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
NCT05248646Immunoglobulin A Nephropathy
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
530
Ahmedabad, Nadiฤd, Bengaluru, Manipal, Kozhikode, Thiruvananthapuram, Aurangabad, Pune
2022-03-15
Active, closed
A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema
NCT05224102Diabetic Macular Edema
Genentech, Inc.
Phase 4
218
Hubli, Pune, Ahmedabad, Chennai, Madurai, Kolkata, Chandigarh
2022-02-28
Active, closed
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
NCT05211895Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
791
Ahmedabad, Bangalore, Delhi, Howrah, Hyderabad, Jaipur, Kolkata, Marg Jaipur
2022-02-18
Active, closed
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
NCT05138133Lupus Nephritis
AstraZeneca
Phase 3
363
Ahmedabad, Dehradun, Delhi, Hyderabad, Kolkata, Nadiฤd, Pune, Secunderabad
2022-02-15
Active, closed
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
NCT05097287Asthma
Sanofi
Phase 4
1,339
Ahmedabad, Chandigarh, Coimbatore, Jaipur, Jodhpur, Kozhikode, Lucknow, Mangaluru
2021-12-16
Active, closed
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
NCT05030428Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals
Phase 3
17,004
Guntur, Hyderabad, Ahmedabad, Vadodara, Belagavi, Manipal, Mysore, Kochi
2021-11-23
Active, closed
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
NCT04958265Atypical Hemolytic Uremic Syndrome
Hoffmann-La Roche
Phase 3
41
Ahmedabad, Gurgaon, New Delhi
2021-11-17
Recruiting
Transfusion Requirements in Younger Patients Undergoing Cardiac Surgery
NCT04754022Disorder, Heart, Postoperative, Cardiac Surgery
Unity Health Toronto
Not applicable
1,440
Ahmedabad
2021-11-01
Rows per page Showing 101–125 of 157
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Indian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 21 September 2026. https://priyalifescience.com/clinical-trials-india/city/ahmedabad

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.